Comparative efficacy and safety of nivolumab-based combination therapies (with ipilimumab or binimetinib) in patients with microsatellite-stable and microsatellite-instability-high metastatic colorectal cancer: a systematic review and meta-analysis [0.03%]
纳武利尤单抗联合伊匹木单抗或贝林妥欧单抗治疗微卫星稳定型和微卫星不稳定型转移性结直肠癌患者的疗效和安全性比较：系统评价和Meta分析
Hussain Abbas,Humayou Ahmed,Hafsa Shuja et al.
Hussain Abbas et al.
Background: Colorectal cancer (CRC) is the third most frequently diagnosed malignancy worldwide and the second leading cause of cancer-related mortality. Despite immune checkpoint inhibitors improving outcomes for patient...
Integrative bioinformatic and experimental analysis reveals prognostic and immunological roles of psychological stress-related genes in skin cutaneous melanoma [0.03%]
整合生物信息学和实验分析揭示心理压力相关基因在皮肤黑色素瘤预后和免疫中的作用
Bin Zheng,Yanglu Ge
Bin Zheng
Background: Skin cutaneous melanoma (SKCM) represents the most aggressive type of skin cancer. Accumulating evidence underscores the critical involvement of chronic psychological stress and depressive states in cancer dev...
Multimodality treatment and survival in primary cardiac malignancies: evidence from competing-risk and machine learning analyses [0.03%]
多模性治疗与原发心脏恶性肿瘤预后的关联：来自竞争风险和机器学习分析的证据
Md Roungu Ahmmad,Morshed Alam,Michael Baine et al.
Md Roungu Ahmmad et al.
Background: Primary cardiac malignancies are rare and highly aggressive, with limited clinical evidence to guide optimal treatment. This study evaluated the association between multimodal treatments and survival outcomes ...
First-line versus second-line use of selpercatinib in treatment of RET fusion-positive advanced non-small cell lung cancer: a cost-effectiveness analysis [0.03%]
塞尔帕替尼治疗RET融合阳性晚期非小细胞肺癌的一线与二线用药的成本效益分析
Kai Wang,Wenjie Liu
Kai Wang
Objective: This study aimed to evaluate the cost-effectiveness of using selpercatinib as a first-line treatment option or reserving it for second-line use versus relying exclusively on chemotherapy in managing RET fusion-...
Exploring tyrosine kinase inhibitors for HER2-positive breast cancer: comprehensive review on a complete pharmacology-molecular mechanisms, safety profiles, and insights from preclinical and clinical studies [0.03%]
HER2阳性乳腺癌的酪氨酸激酶抑制剂研究：药物分子机制、安全性及临床前和临床试验启示的全面综述
Meghraj V Suryawanshi,Rukaiya T Girase,Vishal S Bagul et al.
Meghraj V Suryawanshi et al.
Breast cancer involves complex molecular mechanisms, with elevated expression of various tyrosine kinase receptors correlating with unfavorable outcomes. Tyrosine kinase inhibitors are targeted cancer therapeutics that disrupt signaling pat...
Andrés Jesús Muñoz Martín,Angela Lamarca,Jesus M Banales et al.
Andrés Jesús Muñoz Martín et al.
Heterogeneity in primary gastrointestinal DLBCL: from clinical management to molecular mechanisms and treatment strategies [0.03%]
原发性胃肠道DLBCL的异质性：从临床管理到分子机制和治疗策略
Xiaohong Liu,Daoming Zhang,Le Xu et al.
Xiaohong Liu et al.
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL), with approximately 30%-40% of cases occurring in extranodal organs. Primary gastrointestinal diffuse large B cell lymphoma (PGI-DLBCL) is a predomi...
Multidisciplinary consensus recommendations for the management of IDH-mutant grade 2 gliomas in Spain: a Delphi study [0.03%]
西班牙IDH突变二级胶质瘤的多学科共识管理建议：德尔菲研究
Inés Esparragosa Vázquez,Inmaculada Fortes de la Torre,Amaya Hilario et al.
Inés Esparragosa Vázquez et al.
Purpose: Management of IDH-mutant grade 2 gliomas is challenging due to tumor heterogeneity and uncertainties arising from new imaging modalities, diagnostic advances, and emerging targeted therapies. This study aimed to ...
Circulating tumor DNA-based detection of molecular residual disease in isocitrate dehydrogenase-mutant cholangiocarcinoma for biomarker-guided therapy [0.03%]
基于循环肿瘤DNA的检测异柠檬酸脱氢酶突变型胆管癌分子残留病以指导生物标志物治疗
Alexei Valerievich Yumashev,Boymuradov Shuxrat,Kasimov Khayotbek et al.
Alexei Valerievich Yumashev et al.
Cholangiocarcinoma (CCA), particularly the IDH-mutant subtype, presents major clinical challenges because it is frequently diagnosed at an advanced stage and carries a high risk of postoperative recurrence. Detecting minimal residual diseas...
Trends in male breast cancer in Spain, 1999-2023: a nationwide analysis of incidence and mortality [0.03%]
西班牙1999-2023年男性乳腺癌的流行趋势：一项关于发病率和死亡率的全国范围分析
Lucía Cayuela,Victoria Achaval,Gema Flox-Benítez et al.
Lucía Cayuela et al.
Background: Male breast cancer (MBC) is rare and increasing globally, with limited data on trends in Spain. The study examines MBC trends, incidence, and mortality over a 25 year period (1999-2023) to guide public health ...